Glaxo says its Covid-19 antibody drug works against Omicron
UK drugmaker and partner Vir have now tested the therapy against the whole spike of the mutated variant
UK drugmaker and partner Vir have now tested the therapy against the whole spike of the mutated variant
GlaxoSmithKline PLC and Vir Biotechnology Inc. said their Covid-19 antibody treatment retained effectiveness against the Omicron variant in laboratory studies, even as early data suggests that similar treatments work less well against the highly mutated strain.